Scholar Rock Holding Corp. (SRRK) Prices 2.949M Share Common Offering at $39/Sh; Prices 2.18M Prefunded Warrants at $38.99/Warrant

Go back to Scholar Rock Holding Corp. (SRRK) Prices 2.949M Share Common Offering at $39/Sh; Prices 2.18M Prefunded Warrants at $38.99/Warrant

Pre-Open Stock Movers 10/28: (TUP) (CHY) (FSLR) Higher; (BBBY) (SIX) (SUM) Lower (more...)

October 28, 2020 9:27 AM EDT

Today's Pre-Open Stock Movers:

Tupperware Brands (NYSE: TUP) 20.3% HIGHER; reported Q3 EPS of $1.20, $0.83 better than the analyst estimate of $0.37. Revenue for the quarter came in at $477.2 million versus the consensus estimate of $362.75 million.

Community Health Systems (NYSE: CYH) 13.7% HIGHER; reported Q3 EPS of $0.18, $0.34 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.13 billion... More

After-Hours Stock Movers 10/27: (SRRK) (CYH) (FSLR) Higher; (SUM) (BGFV) (CHRW) Lower (more...)

October 27, 2020 6:02 PM EDT

Today's After-Hours Stock Movers:

Scholar Rock Holding Corporation (Nasdaq: SRRK) 23% HIGHER; announced that it intends to offer and sell in an underwritten public offering $150,000,000 of shares of its common stock. Stock extending Tuesday's 119% stock rise following positive data.

Community Health Systems (NYSE: CYH) 13.7% HIGHER; reported Q3 EPS of $0.18, $0.34 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.13 billion versus the consensus estimate of $2.9 billion.

First Solar (NASDAQ:... More

Scholar Rock Holding Corp. (SRRK) to Offer $150M in Common Stock

October 27, 2020 4:20 PM EDT

Scholar Rock Holding Corporation (Nasdaq: SRRK) announced that it intends to offer and sell in an underwritten public offering $150,000,000 of shares of its common stock. In addition, Scholar Rock intends to grant the underwriters a 30-day option to purchase up to an additional... More

Scholar Rock (SRRK) PT Raised to $52 at BMO Capital

October 27, 2020 3:39 PM EDT

BMO Capital analyst Do Kim raised the price target on Scholar Rock (NASDAQ: SRRK) to $52.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented, "We raise our SRK-015 estimates and target price to $52 from $33, as our probability of success increase to 50% from 33%, following... More

Scholar Rock (SRRK) PT Raised to $33 at Wedbush, After Company Releases Clinical Trial Data

October 27, 2020 12:30 PM EDT

Wedbush analyst David Nierengarten raised the price target on Scholar Rock (NASDAQ: SRRK) to $33.00 (from $23.00) while maintaining a Outperform rating.

... More

Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA

October 27, 2020 7:14 AM EDT

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive six-month interim analysis results from the TOPAZ Phase 2 clinical trial. Treatment with SRK-015 led to improvements in Hammersmith scale scores (primary efficacy endpoint) in all... More